Impact assessment: European Commission explains basis for ATPs
This article was originally published in Clinica
Executive Summary
There was absolutely no doubt in the minds of the European Commission experts, when it came to arguing the case of whether a new regulatory framework was needed for human tissue engineered products (hTEPs), that this was indeed essential for the sake of clarity for business, in order to remove obstacles to free trade and to ensure patients benefit from the innovative therapies they offer.